ライフサイエンスコーパス: oral poliovirus vaccine

1 schedule of ages 6 and 10 weeks, along with oral poliovirus vaccine.

2 tbreaks were controlled within 6 months with oral poliovirus vaccine.

3 , 10.9 to 13.2), when her child received the oral poliovirus vaccine.

4 tion (WHO) recommends the discontinuation of oral poliovirus vaccine after eradication of wild poliov

5 type 1 oral poliovirus vaccine and trivalent oral poliovirus vaccine against type 1 paralytic poliomy

6 the estimated efficacy per dose of trivalent oral poliovirus vaccine against type 3 paralytic poliomy

7 on assay for detecting response to trivalent oral poliovirus vaccine among 224 infants.

8 ired the withdrawal of Sabin type 2 from the oral poliovirus vaccine and introduction of one or more

9 ed the field efficacies of monovalent type 1 oral poliovirus vaccine and trivalent oral poliovirus va

10 ted efficacies per dose of monovalent type 1 oral poliovirus vaccine and trivalent oral poliovirus va

11 he introduction of newly licensed monovalent oral poliovirus vaccines and new techniques of vaccine d

12 accine (four times as effective as trivalent oral poliovirus vaccine) and the moderate gains in cover

13 those who received azithromycin or placebo, oral poliovirus vaccine, and provided a blood sample acc

14 his is critical for the phased withdrawal of oral poliovirus vaccine, beginning with the type 2 compo

15 s vaccine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) and global introduction o

16 3 and the impact of bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) use in immunization campa

17 Participants received IPV, bivalent 1 and 3 oral poliovirus vaccine (bOPV), or no vaccine.

18 Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expecte

19 eduction (0.66; .44-1.00) when censoring for oral poliovirus vaccine campaigns.

20 specified an analysis censoring follow-up at oral poliovirus vaccine campaigns.

21 Oral poliovirus vaccine can mutate to regain neurovirule

22 text of making decisions about the timing of oral poliovirus vaccine cessation following global eradi

23 omycin did not improve the immunogenicity of oral poliovirus vaccine despite reducing biomarkers of e

24 years earlier) the patient received his last oral poliovirus vaccine dose, approximately 2 years befo

25 d an established poliovirus transmission and oral poliovirus vaccine evolution model to characterize

26 existing dynamic poliovirus transmission and oral poliovirus vaccine evolution model.

27 The higher efficacy of monovalent type 1 oral poliovirus vaccine (four times as effective as triv

28 the immunogenicity of serotype-3 monovalent oral poliovirus vaccine given to healthy infants living

29 hat has recently demonstrated activity in an oral poliovirus vaccine human challenge model.

30 ycin or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004

31 is finding is probably affected by the lower oral poliovirus vaccine immunogenicity previously demons

32 to assess whether antibiotics would improve oral poliovirus vaccine immunogenicity.

33 ssess the immunogenicity of the new bivalent oral poliovirus vaccine + inactivated poliovirus vaccine

34 18-week-old infants vaccinated with bivalent oral poliovirus vaccine/inactivated poliovirus vaccine r

35 Oral poliovirus vaccine is less immunogenic and effectiv

36 itions where the efficacy of live-attenuated oral poliovirus vaccines is compromised by a high preval

37 l, particularly in assays of live attenuated oral poliovirus vaccine lots.

38 vision of several doses of monovalent type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3

39 ssed the immunogenicity of monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than us

40 ion activities (SIAs) with monovalent type 2 oral poliovirus vaccine (mOPV2) and novel type 2 oral po

41 Monovalent type 2 oral poliovirus vaccine (mOPV2) stockpile is low.

42 The monovalent type 2 oral poliovirus vaccine (mOPV2) stockpile is low.

43 nogenic polio vaccines, including monovalent oral poliovirus vaccines (mOPVs), are needed for supplem

44 poliovirus vaccine (mOPV2) and novel type 2 oral poliovirus vaccine (nOPV2) targeted an estimated 35

45 or 3 days, followed by serotype-3 monovalent oral poliovirus vaccine on day 14.

46 The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicate

47 e number of newborns given the first dose of oral poliovirus vaccine (OPV) according to the RI schedu

48 lio Eradication Initiative plans to stop all oral poliovirus vaccine (OPV) after wild poliovirus erad

49 cting immunogenicity of the first 2 doses of oral poliovirus vaccine (OPV) among unimmunized Mayan in

50 Interference between oral poliovirus vaccine (OPV) and monovalent (RRV-S1) an

51 ity profile after routine doses of trivalent oral poliovirus vaccine (OPV) and numerous supplemental

52 ed to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence o

53 era, epitope-specific monoclonal murine anti-oral poliovirus vaccine (OPV) antibodies, and sera from

54 and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequenti

55 ins of poliovirus used in the manufacture of oral poliovirus vaccine (OPV) are prone to genetic varia

56 ths after vaccination with monovalent type 1 oral poliovirus vaccine (OPV) at 6 months and trivalent

57 lected children (0-15 years of age) received oral poliovirus vaccine (OPV) challenge dose.

58 ng model expectations with the experience of oral poliovirus vaccine (OPV) containing serotype 2 (OPV

59 e children whose caregivers refuse to accept oral poliovirus vaccine (OPV) contributes to the spread

60 The effect of diarrhea on oral poliovirus vaccine (OPV) failure was evaluated usin

61 on on immunisation activities with different oral poliovirus vaccine (OPV) formulations, and serotype

62 Since the global withdrawal of Sabin 2 oral poliovirus vaccine (OPV) from routine immunization,

63 The attenuated oral poliovirus vaccine (OPV) has many properties favori

64 Oral poliovirus vaccine (OPV) has not been used in the U

65 srael due to past exposure to WPV and use of oral poliovirus vaccine (OPV) in addition to IPV.

66 will entail eventual cessation of the use of oral poliovirus vaccine (OPV) in all countries to preven

67 is challenged by notions against the role of oral poliovirus vaccine (OPV) in eradicating contemporar

68 ared the immune response to IPV with that to oral poliovirus vaccine (OPV) in Guatemalan infants.

69 The impaired immunogenicity of oral poliovirus vaccine (OPV) in low-income countries ha

70 parents/caregivers if the child received any oral poliovirus vaccine (OPV) in Myanmar and, for younge

71 Withdrawal of type 2 oral poliovirus vaccine (OPV) in OPV-using countries req

72 Replication of Sabin strains used in oral poliovirus vaccine (OPV) in the intestines of vacci

73 ut the degree of mucosal immunity induced by oral poliovirus vaccine (OPV) in tropical countries.

74 that all 124 countries currently using only oral poliovirus vaccine (OPV) introduce at least 1 dose

75 Mucosal immunity induced by oral poliovirus vaccine (OPV) is imperfect and potential

76 Intestinal immunity induced by oral poliovirus vaccine (OPV) is imperfect and wanes wit

77 Trivalent oral poliovirus vaccine (OPV) is known to interfere with

78 Oral poliovirus vaccine (OPV) is less immunogenic in low

79 Each lot of oral poliovirus vaccine (OPV) is tested for neurovirulen

80 virome in affecting immune responses to the oral poliovirus vaccine (OPV) is unknown.

81 en 23 of 34 SIAs used monovalent or bivalent oral poliovirus vaccine (OPV) lacking Sabin 2.

82 o before, throughout, and after the May 2010 oral poliovirus vaccine (OPV) mass immunization campaign

83 mune deficiency disorders (PIDD) who receive oral poliovirus vaccine (OPV) may transmit immunodeficie

84 tion is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued becau

85 oliovirus vaccine in all 126 countries using oral poliovirus vaccine (OPV) only as of 2012, (2) full

86 ramuscularly, among adults with a history of oral poliovirus vaccine (OPV) receipt.

87 Oral poliovirus vaccine (OPV) results in an ongoing burd

88 the current national 4-dose live attenuated oral poliovirus vaccine (OPV) schedule with a 4-dose IPV

89 otide sequence identity) to the Sabin type 2 oral poliovirus vaccine (OPV) strain and unrelated (<82%

90 VDPV isolates differed from the Sabin type 1 oral poliovirus vaccine (OPV) strain at 1.84% to 3.15% o

91 efore and after a September 2007 switch from oral poliovirus vaccine (OPV) to IPV, using standard cov

92 hip existed between the failure of trivalent oral poliovirus vaccine (OPV) to prevent poliomyelitis a

93 Novel oral poliovirus vaccine (OPV) type 2 (nOPV2) has been ma

94 int mutation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in conjunc

95 shedding lend to the growing consensus that oral poliovirus vaccine (OPV) use should be discontinued

96 curred in 1979; however, as a consequence of oral poliovirus vaccine (OPV) use that began in 1961, an

97 d in human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomiza

98 Oral poliovirus vaccine (OPV) was not available in Samar

99 ion, and carrying-out mopping-up activities, oral poliovirus vaccine (OPV) was selected as the vaccin

100 cure a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will eventually need to be

101 other orally administered vaccines, such as oral poliovirus vaccine (OPV), may also be associated wi

102 22 different interventions were assessed for oral poliovirus vaccine (OPV), oral rotavirus vaccine (R

103 The immunogenicity of oral poliovirus vaccine (OPV), particularly the type 3 c

104 ity of routine versus mass campaign doses of oral poliovirus vaccine (OPV), serum neutralizing antibo

105 The live, attenuated oral poliovirus vaccine (OPV), used for more than four d

106 Early trials suggested that oral poliovirus vaccine (OPV), when administered concomi

107 ce significantly lower mucosal immunity than oral poliovirus vaccine (OPV).

108 h very low (7 to 40%) rates of coverage with oral poliovirus vaccine (OPV).

109 munity in children previously immunized with oral poliovirus vaccine (OPV).

110 ed to compare the safety profiles of IPV and oral poliovirus vaccine (OPV).

111 APP) is a rare adverse event associated with oral poliovirus vaccine (OPV).

112 wild poliovirus or those emanating from the oral poliovirus vaccine (OPV).

113 liminate circulating live polioviruses using oral poliovirus vaccine (OPV).

114 ty to enteric viruses, potentially including oral poliovirus vaccine (OPV).

115 es on intestinal mucosal immunity induced by oral poliovirus vaccine (OPV).

116 Sabin strains used in oral poliovirus vaccines (OPV) can revert to virulence a

117 OCV and oral poliovirus vaccines (OPV) could be administered con

118 alculate clinical efficacy estimates for the oral poliovirus vaccines (OPV) currently in use.

119 Serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild

120 Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1

121 Global withdrawal of serotype-2 oral poliovirus vaccine (OPV2) took place in April 2016.

122 he withdrawal of the serotype 2 component of oral poliovirus vaccine (OPV2) was implemented in April

123 atients had received at least three doses of oral poliovirus vaccine (OPV3).

124 poliovirus requires the global withdrawal of oral poliovirus vaccines (OPVs) and replacement with ina

125 ine-derived polioviruses (cVDPV2) from Sabin oral poliovirus vaccines (OPVs) are the leading cause of

126 Supplementary immunisation activities with oral poliovirus vaccines (OPVs) are usually separated by

127 ssociated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs) has stimulated developme

128 es to estimate the clinical effectiveness of oral poliovirus vaccines (OPVs) in Afghanistan and Pakis

129 of seropositivity was the number of doses of oral poliovirus vaccine received (P < .01), with levels

130 d may be predicted by the number of doses of oral poliovirus vaccine received.

131 % received the third dose of pentavalent and oral poliovirus vaccine, respectively, but only 65% rece

132 Repeated administration of oral poliovirus vaccine resulted in progressively shorte

133 d by this manufacturer to inactivate SV40 in oral poliovirus vaccine seed stocks based on heat inacti

134 r determinants of attenuation of the Sabin 2 oral poliovirus vaccine strain (A481 in the 5'-untransla

135 e (nt 3271 to 3637) derived from the Sabin 1 oral poliovirus vaccine strain spanning the 3'-terminal

136 within the capsid region of the Sabin type 2 oral poliovirus vaccine strain with corresponding nonpre

137 Mass vaccination campaigns with the oral poliovirus vaccine targeting children aged <5 years

138 to eradicate poliomyelitis by administering oral poliovirus vaccine through routine immunization and

139 , where immunization coverage with trivalent oral poliovirus vaccine (tOPV) has been low.

140 been hampered by low responses to trivalent oral poliovirus vaccine (tOPV) in some developing countr

141 the proposed worldwide switch from trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3

142 Replacement of the trivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and

143 pes 1 and 3, compared with that of trivalent oral poliovirus vaccine (tOPV), in South Africa.

144 Novel oral poliovirus vaccine type 2 (nOPV2) has been engineer

145 Novel oral poliovirus vaccine type 2 (nOPV2) was administered

146 Novel oral poliovirus vaccine type 2 (nOPV2) was used to contr

147 osine mutation at nucleotide position 472 of oral poliovirus vaccine type 3 (OPV3) contributes to the

148 Twelve monovalent lots of live, attenuated oral poliovirus vaccine types 1, 2, and 3, which were re

149 coordinated cessation of type 2-containting oral poliovirus vaccine use.

150 type 1 oral poliovirus vaccine and trivalent oral poliovirus vaccine, using the reported number of do

151 ts aged 9-10 months who had already received oral poliovirus vaccine were randomly assigned to receiv

152 opped after multiple vaccination rounds with oral poliovirus vaccine, which targeted the entire popul

153 reviously, we demonstrated the monitoring of oral poliovirus vaccine with the use of mutant analysis

154 ization, the allegations of contamination of oral poliovirus vaccines with human immunodeficiency vir